Table 2.
Overview of the number of subjects corresponding to each predicted optimal interventions, and the combinations of interventions that resulted in the maximal reduction of risk
| Intervention | # of subjects |
|---|---|
| MRA + Exercise + GLP1RA + SGLT2I + ARB | 320 |
| MRA + Exercise + GLP1RA + SGLT2I + Olive oil + ARB | 165 |
| MRA + SGLT2I + ARB | 123 |
| MRA + Exercise + SGLT2I + ARB | 120 |
| MRA + Exercise + ARB | 48 |
| MRA + Exercise + GLP1RA + ARB | 39 |
| MRA + GLP1RA + SGLT2I + ARB | 31 |
| MRA + ARB | 16 |
| MRA + GLP1RA + ARB | 16 |
| SGLT2I + ARB | 15 |
| Exercise + GLP1RA + ARB | 8 |
| ARB | 4 |
| GLP1RA + ARB | 4 |
| GLP1RA + SGLT2I + ARB | 4 |
| MRA + GLP1RA + SGLT2I | 4 |
| Exercise + GLP1RA + SGLT2I + ARB | 2 |
| GLP1RA + SGLT2I | 2 |
| Olive oil | 2 |
| MRA + Exercise + SGLT2I + Olive oil + ARB | 2 |
| MRA + SGLT2I | 2 |
| Exercise + GLP1RA + SGLT2I + Olive oil + ARB | 1 |
| Exercise + SGLT2I + ARB | 1 |
| GLP1RA | 1 |
| SGLT2I | 1 |
| MRA + Exercise + GLP1RA + SGLT2I | 1 |
| MRA + Exercise + SGLT2I | 1 |
| MRA + GLP1RA + Olive oil + ARB | 1 |
| MRA + SGLT2I + Olive oil + ARB | 1 |
ARB angiotensin receptor blockers, GLP1RA Glucagon-like peptide-1 receptor agonist, MRA mineralocorticoid receptor antagonist, SGLT2I sodium-glucose co-transporter 2 inhibitor